56,752 Shares in Haleon plc (NYSE:HLN) Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new position in shares of Haleon plc (NYSE:HLN - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 56,752 shares of the company's stock, valued at approximately $600,000.

Other large investors also recently modified their holdings of the company. Fortitude Family Office LLC bought a new position in Haleon during the third quarter worth $28,000. Cultivar Capital Inc. acquired a new stake in shares of Haleon in the 2nd quarter valued at about $40,000. Prospera Private Wealth LLC bought a new stake in Haleon in the 3rd quarter valued at about $57,000. BOKF NA increased its position in Haleon by 68.8% in the 2nd quarter. BOKF NA now owns 6,972 shares of the company's stock valued at $58,000 after buying an additional 2,842 shares in the last quarter. Finally, Rothschild Investment LLC acquired a new position in Haleon during the 2nd quarter worth approximately $60,000. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Stock Up 0.3 %

Shares of Haleon stock traded up $0.03 on Friday, hitting $9.76. The company had a trading volume of 11,526,562 shares, compared to its average volume of 5,403,752. The stock has a market capitalization of $44.18 billion, a price-to-earnings ratio of 28.71, a P/E/G ratio of 2.95 and a beta of 0.28. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The stock has a 50 day moving average of $9.75 and a 200-day moving average of $9.53.

Wall Street Analyst Weigh In

Several research firms have recently commented on HLN. Morgan Stanley boosted their price objective on Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a report on Friday, September 20th. UBS Group upgraded shares of Haleon to a "strong-buy" rating in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.